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Insulin is the major hormone that regulates hepatic glucose
metabolism by repressing gluconeogenic enzyme-encoding
genes, and the counteracting glucagon/protein kinase
(PKA)–inducible coactivating peroxisome proliferator–
activated receptor g coactivator-1a (PGC-1a) signaling
pathway is also well characterized in hepatic glucose me-
tabolism (1–3). Until now, however, the regulation of the
insulin/protein kinase B (PKB)/Akt–inducible corepressor
signaling pathway has remained largely unknown. Pre-
viously, it was believed that insulin suppression of glu-
coneogenesis was largely mediated through PKB activity
via direct phosphorylation and dephosphorylation mech-
anisms (4). However, in this issue of Diabetes, Lee et al.
(5) dissect the role of the small heterodimer partner–
interacting leucine zipper protein (SMILE) in insulin-
mediated hepatic glucose metabolism. SMILE is a member
of the CREB/ATF family of basic-region leucine zipper
(bZIP) transcription factors and has been reported to
function as a corepressor of nuclear receptor superfamily
genes, including estrogen-related receptor g (ERRg), glu-
cocorticoid receptor (GR), hepatocyte nuclear factor 4a
(HNF4a), and cAMP-responsive element–binding pro-
tein H (CREBH) (6–8). In fact, ERRg, GR, HNF4a, and
CREBH have all been implicated in upregulating gluco-
neogenic gene expression (9–12).
Lee et al. (5) show that SMILE is an insulin-inducible
corepressor that suppresses hepatic gluconeogenesis by
opposing the action of PGC-1a. The hepatic expression
of SMILE is tightly regulated by nutritional status and
is elevated in response to feeding. On the other hand,
refeeding fails to increase SMILE gene expression in in-
sulin-resistant mouse models (db/db and high-fat diet
[HFD]–fed mice). Additionally, liver-speciﬁc insulin re-
ceptor knockout (LIRKO) or PKB b-deﬁcient (PKBb2/2)
mice fail to upregulate SMILE, suggesting that the insu-
lin/PKB pathway plays a major role in regulating SMILE
expression. Also, enforced SMILE expression could down-
regulate hepatic gluconeogenic genes and counter hypergly-
cemia and glucose intolerance in both db/db and HFD-fed
mice. It was also shown that SMILE competes with PGC-1a
for dimerization with HNF4a, attenuating binding to, and
transactivation of, gluconeogenic gene promoters, ultimately
reducing hepatic glucose production (5).
It is well known that the action of insulin in suppressing
gluconeogenesis is rapid due to dynamic phosphoryla-
tion and dephosphorylation of its downstream signal
pathway components. Here, Lee et al. (5) demonstrate
that the delayed effect of insulin regulation on gluco-
neogenesis very likely depends on the induction of the
SMILE corepressor. Interestingly, in early insulin response,
SMILE knockdown did not affect insulin-mediated re-
pression, while at later time points, insulin-mediated
repression of gluconeogenic gene expression (or hepatic
glucose output) was signiﬁcantly relieved by SMILE
knockdown. This proposed mechanism was then tested
in vivo to validate a critical role for SMILE in hepatic
glucose metabolism, showing that ablation of SMILE
signiﬁcantly elevated blood glucose levels. In contrast,
overexpression of SMILE improved fasting blood glu-
cose levels and glucose/pyruvate tolerance in db/db and
HFD-fed mice. Thus, this work represents a compre-
hensive examination of the mechanisms whereby insu-
lin action of delayed response may be achieved through
SMILE in the regulation of hepatic glucose metabolism.
Insulin is known to increase lipogenic gene expression
through the sterol regulatory element–binding transcrip-
tion factor-1c (SREBP-1c), which Lee et al. (5) show to
upregulate SMILE. However, previous studies by this same
group also showed that SMILE downregulates liver X recep-
tor a (LXRa)–mediated hepatic lipogenic gene expression
(13). To explain this paradox, it will be important to assess
the physiological relevance of SMILE on the expression of
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gluconeogenic and lipogenic enzyme genes. In addition,
assessment of the effects of SMILE activity on the cel-
lular physiology of speciﬁc tissues will require SMILE
tissue-speciﬁc knockout mouse models.
A previous report demonstrated that hepatic gluco-
neogenesis is also decreased due to the inhibition of HNF4a
activity by DAX-1, which itself is an insulin-inducible
corepressor of nuclear receptors (11), suggesting a re-
dundancy of insulin-inducible corepressor-mediated in-
hibition of hepatic gluconeogenesis. Consequently, the
relative contribution of these two nuclear receptors in
mediating insulin-dependent regulation of hepatic gluco-
neogenesis should also be assessed in the future.
It was previously reported that hepatic SMILE expres-
sion can be induced by curcumin and ursodeoxycholic acid
(UDCA) in an AMPK-dependent fashion (8,13), suggest-
ing that the pharmacological activation of SMILE expres-
sion might also be used as a new therapeutic strategy to
treat hyperglycemia. To that end, however, assessment of
altered SMILE expression or activity in patients with diabe-
tes will be necessary for developing antihyperglycemia drugs.
Overall, the study by Lee et al. (5) purports that SMILE
counteracts the stimulatory effect of PGC-1a on hepatic
gluconeogenesis while also playing an important role in
insulin-signaling effects on hepatic glucose metabolism.
Under fasting conditions, the PKA/PGC-1a pathway
increases hepatic gluconeogenesis, while in the fed con-
dition, the PKB/SMILE pathway silences PGC-1a–in-
duced hepatic gluconeogenesis (Fig. 1). In addition to
HNF4a, other transcription factors interacting with
SMILE, including ERRg, GR, CREBH, and/or FOXO1
(6–8), might mediate the inhibitory effects of insulin on
gluconeogenic gene expression (9,11,12). To summarize,
the article by Lee et al. (5) demonstrates that the nuclear
orphan receptor SMILE plays a large role in the homeo-
static regulation of hepatic gluconeogenesis and that cor-
rection of its aberrant activity (possibly via pharmacological
agents) represents a promising avenue for the therapy of
metabolic disease.
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Figure 1—Gluconeogenic gene expression is regulated by core-
pressors and coactivators during fed and fasting states, respec-
tively. During the fed state, insulin induction of SMILE increases
the formation of SMILE transcription factor (TF) duplexes, resulting
in the repression of gluconeogenic genes such as G6Pase and
PEPCK. Conversely, during fasting, glucagon upregulates PGC-
1a, which binds to TFs, resulting in the induction of gluconeogenic
gene expression. TFs are HNF4a, FOXO1, GR, ERRg, and CREBH,
for example.
diabetes.diabetesjournals.org Kim and Ahn 15
